These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1523 related articles for article (PubMed ID: 8687231)

  • 1. [The potential of interleukin-12 for use in cancer therapy].
    Gately MK; Brunda MJ
    Gan To Kagaku Ryoho; 1996 Jul; 23(8):961-71. PubMed ID: 8687231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-12: potential role in cancer therapy.
    Brunda MJ; Gately MK
    Important Adv Oncol; 1995; ():3-18. PubMed ID: 7672811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
    Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
    Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
    Lasek W; Golab J; Maśliński W; Switaj T; Bałkowiec EZ; Stokłosa T; Giermasz A; Malejczyk M; Jakóbisiak M
    Eur Cytokine Netw; 1999 Sep; 10(3):345-56. PubMed ID: 10477391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-12: biological properties and clinical application.
    Del Vecchio M; Bajetta E; Canova S; Lotze MT; Wesa A; Parmiani G; Anichini A
    Clin Cancer Res; 2007 Aug; 13(16):4677-85. PubMed ID: 17699845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases.
    Gately MK; Gubler U; Brunda MJ; Nadeau RR; Anderson TD; Lipman JM; Sarmiento U
    Ther Immunol; 1994 Jun; 1(3):187-96. PubMed ID: 7584494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
    Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity.
    Matsuse H; Kong X; Hu J; Wolf SF; Lockey RF; Mohapatra SS
    Int Immunopharmacol; 2003 Apr; 3(4):457-68. PubMed ID: 12689651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-12. Biologic activity, therapeutic utility, and role in disease.
    Hendrzak JA; Brunda MJ
    Lab Invest; 1995 Jun; 72(6):619-37. PubMed ID: 7783421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological properties and clinical significance of interleukins 12 (IL-12)].
    Marańda E; Robak T
    Postepy Hig Med Dosw; 1998; 52(5):489-506. PubMed ID: 9857673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
    Eguchi J; Hiroishi K; Ishii S; Mitamura K
    Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
    Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
    Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
    Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
    Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.